The compensation milestones are hidden at the very end of the filing.
Note the requirement of the stock price and the date by which this is to occur. It is number (4)
Management milestones that affect cash bonuses
Successful administration of any Ampion TM , Optina TM and Zertane TM clinical trials financed by the company. Successful shall mean that the trial was performed on time and on budget and with a demonstration of efficacy that is statistically significant and the drug is cleared for commercialization by the regulatory authorities in all countries in which commercialization is planned.
2) Obtain, on terms favorable to the company, license agreement, partnerships or other collaborations for the commercialization of the company’s drug portfolio
3) Obtain insurance reimbursement codes for each drug that receives regulatory clearance to commercialize
4) Within 6 months of the date of this agreement, obtain $15 million in equity financing for the company at a share price in excess of $5/share
yes, I meant Disbrow.
Please read the post SEC filing Dec 19th. I posted it in case you can't find it this morning-- it's an attachment AMPIO made to the filing. It's long and at the very end it shows Disbrow's milestones he must reach in order to vest his options.
It is both good and bad. Good in that it shows that the company plans to get the stock to $5 within 6 months of the filing of the Dec 19th form. Bad in the sense it will be further dilution of shares. And that is not to mention the unstated intentions of management to sell their shares.
I have no idea of Disbrow's connections with mutual funds/retirement funds managers to get this much money. No connections with ivy league graduates, but with someone(s) since he's done this with the previous company he has worked for.